BIOVERATIV INC (NASDAQ:BIVV) reported Q2 2017 earnings this Afternoon, coming in at $0.88 per share, beating Wall Street’s estimates of $0.71 per Share. Revenue for the quarter came in at $289.10 million beating analyst estimates of $269.00 million
Analyst Coverage For BIOVERATIV INC (NASDAQ:BIVV)
These are 1 Sell Rating, 7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for BIOVERATIV INC (NASDAQ:BIVV) is Hold (Score: 2.43) with a consensus target price of $55.42 , a potential (9.49% downside)Recent Insider Trading for BIOVERATIV INC (NASDAQ:BIVV)
- On 6/28/2017 Diantha Duvall, Insider, sold 818 with an average share price of $60.47 per share and the total transaction amounting to $49,464.46.
- On 5/30/2017 Alexander J Denner, Director, bought 90,000 with an average share price of $55.93 per share and the total transaction amounting to $5,033,700.00.
- On 5/26/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $57.76 per share and the total transaction amounting to $115,520.00.
- On 5/24/2017 Brian S Posner, Director, bought 2,000 with an average share price of $53.86 per share and the total transaction amounting to $107,720.00.
Recent Trading for BIOVERATIV INC (NASDAQ:BIVV) Shares of BIOVERATIV INC closed the previous trading session at 61.23 up +0.34 0.56% with 1,211,803 shares trading hands.